AnaptysBio (NASDAQ:ANAB) Releases Earnings Results, Beats Expectations By $0.58 EPS

AnaptysBio (NASDAQ:ANAB) announced its quarterly earnings data on Tuesday. The biotechnology company reported ($1.14) EPS for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58, Zacks reports. The business had revenue of $30.02 million for the quarter, compared to analyst estimates of $7.92 million. AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%.

AnaptysBio Trading Down 1.3 %

NASDAQ ANAB traded down $0.28 during trading on Friday, reaching $21.21. The company’s stock had a trading volume of 136,236 shares, compared to its average volume of 347,009. AnaptysBio has a 12 month low of $13.36 and a 12 month high of $41.31. The firm has a 50 day moving average price of $33.00 and a 200 day moving average price of $29.83. The firm has a market capitalization of $581.79 million, a price-to-earnings ratio of -3.38 and a beta of -0.24.

Insider Activity at AnaptysBio

In other news, CFO Dennis Mulroy sold 12,220 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $39.91, for a total transaction of $487,700.20. Following the sale, the chief financial officer now directly owns 4,744 shares of the company’s stock, valued at approximately $189,333.04. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other AnaptysBio news, major shareholder Ecor1 Capital, Llc purchased 273,972 shares of the stock in a transaction dated Wednesday, August 14th. The stock was bought at an average price of $36.50 per share, with a total value of $9,999,978.00. Following the acquisition, the insider now owns 7,794,996 shares of the company’s stock, valued at approximately $284,517,354. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Dennis Mulroy sold 12,220 shares of the firm’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $39.91, for a total value of $487,700.20. Following the completion of the sale, the chief financial officer now directly owns 4,744 shares in the company, valued at $189,333.04. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 22,440 shares of company stock worth $892,936. Company insiders own 33.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. JPMorgan Chase & Co. raised their price objective on AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. UBS Group upped their price objective on AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Wedbush restated an “outperform” rating and set a $42.00 target price on shares of AnaptysBio in a report on Wednesday. Guggenheim increased their price target on shares of AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Finally, Truist Financial lifted their price objective on shares of AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a research report on Thursday, August 15th. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $55.45.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.